incretin hormone glp-1 Incretin-based therapy of metabolic disease GIP and GLP-1 as incretin

Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice

Healthy habits remain the foundation of lifelong metabolic wellness

We often recommend electrolyte supplementation as part of our GLP-1 management protocols. While these medications offer tremendous benefits for weight management and diabetes control, there are times when you might need to reconsider continued use: At Klarity Health, we work closely with patients to determine whether symptoms warrant a medication pause, dose adjustment, or different management strategy, notes Dr

Dose reduction or discontinuation may be necessary if you develop: Persistent, intolerable gastrointestinal symptoms despite supportive measures Acute pancreatitis (discontinue permanently) Severe hypoglycemia, particularly if taking concurrent insulin or sulfonylureas Acute kidney injury or worsening renal function Gallbladder disease symptoms (abdominal pain, jaundice) Diabetic retinopathy complications (particularly with semaglutide) Severe hypersensitivity reactions including anaphylaxis or angioedema Pregnancy or plans for pregnancy (for semaglutide, discontinue at least two months before planned conception